Expertise

Dr. Richard Stefanacci

Chief Medical Director

EVERSANA

Dr. Richard Stefanacci

Richard has focused his career on improving health outcomes, especially for some of the most vulnerable populations. This has been achieved through several avenues, beginning with his continued active role as a treating internist/geriatrician. He has also put this focus into practice as chief medical officer for several management care plans, including ElderHealth/Bravo/HealthSpring/Cigna and PACE (Program for All-inclusive Care for the Elderly) programs, as well as his current role as a pharmacy and therapeutics committee member for several national plans. On the policy side, Richard served as health policy scholar for the Centers for Medicare & Medicaid Services (CMS) through his role at Thomas Jefferson University, College of Population Health, where he maintains a faculty appointment. He has over 500 publications in addition to delivering well over 1,000 lectures, both nationally and internationally, focused on improving health outcomes. Today, Richard is actively engaged in leading population health activities for numerous health systems and payer groups.

His recognized expertise has led to Richard being appointed to serve on the American Society of Consultant Pharmacists (ASCP) and the AMDA Foundation boards, as well as being honored as an honorary lifetime member of the ASCP and the National Association of Directors of Nursing. Richard has achieved recognition as a fellow in both the College of Physicians of Philadelphia and the American Geriatric Society and was recently awarded the Humanism in Aging Leadership Award from the University of New England.

Richard’s work for vulnerable populations is very personal, stemming from his involvement with the Go4theGoal Foundation (www.Go4theGoal.org), a 501(c)(3) public charity that he founded with his family and friends when his oldest son, Richard, was diagnosed with Ewing’s sarcoma. Since its inception, the foundation has raised several million dollars to assist hundreds of children affected by cancer at nearly 100 children’s hospitals across the country, while also funding cutting-edge research to find a cure. This research work is directed by the foundation’s panel of experts, which includes several current and past federal government leaders in rare diseases.

Richard holds a DO and an MS in geriatric healthcare from the A.T. Still University of Health Sciences, as well as an MBA from the Keller Graduate School of Management of DeVry University. He is also an American Geriatrics Society Fellow and a certified medical dosimetrist.

Expertise:

Affordability Programs (PAP, Copay), Pricing, Reimbursement & Market Access, Stakeholder Engagement & Promotion (Patients, Payers, Providers)

Articles by Dr. Richard Stefanacci

Federal Enforcement of Clinical Pathways Resource Utilization Management

Providers order unnecessary tests for a variety of reasons: pressure from patients, fears of malpractice suit, not being knowledgeable about current “best” practices as well as for potential financial advantage for them or their health system. Clinical pathways built on solid clinical guidelines have the potential to lower costs through reduced resource utilization of potentially, […]

Ramifications of “Medicare for All” and Implications for Clinical Pathways

As the Medicare for All (M4A) debate continues into 2020, clinical pathway organizations, payers, health systems, providers, and patients will all play a role in shaping future policies around patient access and reimbursement. While it is certain that clinical pathways are shaping and will continue to shape health care regardless of system, what is far […]

Reimbursement Dynamics for Women’s Health Drugs

EVERSANA’s Dr. Richard Stefanacci shares insights in a GlobalData News article on reimbursement dynamics for drugs in the women’s health space, particularly for endometriosis-related pain and uterine fibroids. Dr. Stefanacci provided the following content to the reporter prior to the interview, covering the key stakeholders perspectives: For Prescription Drug Plans – The challenge is shifting […]

Balancing Access

Value propositions need to justify product pricing by focusing on the burden of severe illnesses and how the products address unmet needs.

Could CMS Policies Impact Investments in CAR T-cell Therapies and Other Innovative Treatments?

Clinical pathways that include CAR T-cell therapy as an option must integrate appropriate guidance on its use and settings of care.

Interested in scheduling a meeting or speaking event?

Contact Us

  • This field is for validation purposes and should be left unchanged.